Stock Ratings / Health Care / XFOR / dividends

ALEC (32) SCTX (50) IRLA (32) AGEN (26) ⌘ Pro Terminal →

X4 Pharmaceuticals Inc. (XFOR) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.36 +0.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

X4 Pharmaceuticals Inc. (XFOR) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $333.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XFOR)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.7K

Yr 3

$18.3K

Yr 4

$21.3K

Yr 5

$24.7K

Yr 6

$28.8K

Yr 7

$33.5K

Yr 8

$38.9K

Yr 9

$45.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XFOR)

✓Walkthrough of XFOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XFOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.44%📐 HORIZONTAL RANGE

2026-10-30O $3.33H $3.41L $3.19C $3.36VOL 706.2K

RES: $5.03SUP: $2.20SMA50: $3.33SMA200: $3.80

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XFOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XFOR Butterfly Map → + Track XFOR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XFOR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XFOR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XFOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XFOR)

Health Care Rank #817 of 1016 ⚔️ ALEC vs XFOR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XFOR vs. ALEC, SCTX, IRLA, AGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, X4 Pharmaceuticals Inc. (XFOR) ranks #817 by composite RQD confidence (35/100, grade D-) and #507 by equity capitalization ($333.1M). Within this direct 5-issuer industry benchmark cohort, XFOR leads on earnings valuation at N/A trailing P/E, while XFOR leads on capital efficiency and profitability with -35.0% ROIC and 83.6% gross margin. SCTX currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with XFOR at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XFOR ACTIVE X4 Pharmaceuticals Inc.	D-	35/100	—	83.6%	-35.0%	+0.30%	$333.1M	Benchmark Subject
ALEC Alector Inc.	E	32/100	—	—	-35.0%	-0.44%	$332.1M	/alec-vs-xfor →
SCTX Scribe Therapeutics Inc.	D	50/100	—	—	—	-0.57%	$330.2M	/sctx-vs-xfor →
IRLA IRulya Therapeutics Inc.	E	32/100	—	—	-35.0%	-4.05%	$342.8M	/irla-vs-xfor →
AGEN Agenus Inc.	E	26/100	—	96.0%	-35.0%	-0.56%	$320.2M	/agen-vs-xfor →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001501697

In its most recent audited fiscal period (FY2025, filed 2025-12-31), X4 Pharmaceuticals Inc. (XFOR) reported GAAP revenue of $35.1M (+1273.2% vs. FY2024 revenue of $2.6M ) , GAAP net income of -$79.2M, operating cash flow of -$85.6M, and free cash flow of -$85.6M (+34.8% YoY). On the balance sheet, XFOR closed FY2025 with $290.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$35.1M	-$79.2M	-$85.6M	-$85.6M	$290.5M	—
FY2024 (FY)	2024-12-31	$2.6M	-$37.5M	-$130.9M	-$131.2M	$146.4M	—
FY2023 (FY)	2023-12-31	$0	-$101.2M	-$96.5M	-$96.5M	—	—

3. XFOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XFOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, X4 Pharmaceuticals Inc. (NASDAQ: XFOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.36 (+0.30% 1D, market cap $333.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XFOR ranks #817 in composite RQD confidence.

How does XFOR compare to ALEC and SCTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), XFOR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 83.6%, and ROIC of -35.0%. By comparison, ALEC (Alector Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M) and SCTX (Scribe Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $330.2M). Among the 5-stock peer group, XFOR leads on earnings multiple (N/A) while XFOR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XFOR?

Per XFOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501697), X4 Pharmaceuticals Inc. generated $35.1M in revenue (+1273.2% YoY), -$79.2M in net income, and -$85.6M in free cash flow against $290.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XFOR trading relative to its 50-day, 200-day, and 52-week technical levels?

XFOR last traded at $3.36 (+0.30% on volume of 911,233 shares), positioning the stock +0.90% above its 50-day simple moving average ($3.33) and -11.58% below its 200-day simple moving average ($3.80). Across its 52-week range of $2.43 to $4.83, XFOR sits at the 38.7% percentile with a 14-day RSI of 60.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.94 to $3.78).

XFOR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does XFOR pay a dividend and is it safe?

X4 Pharmaceuticals Inc. (XFOR) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: XFOR RQD Cockpit XFOR 12M Forecast XFOR Earnings & Move XFOR Dividends & DRIP XFOR Insiders & 13F XFOR Whale Options XFOR Profit Sankey XFOR News & Why